Darcy Mootz
Director/Board Member at ELEVATION ONCOLOGY, INC.
Net worth: - $ as of 2024-06-29
Profile
Darcy Mootz is an Independent Director at Elevation Oncology, Inc. They previously worked as a Senior Director-Corporate Development at Achaogen, Inc., a Director at Alpha-9 Oncology, Inc., and as the Chief Business Officer at Oric Pharmaceuticals, Inc. Dr. Mootz completed their undergraduate degree at Duke University and their doctorate at Harvard University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ELEVATION ONCOLOGY, INC.
-.--% | 2024-06-12 | 0 ( -.--% ) | - $ | 2024-06-29 |
Darcy Mootz active positions
| Companies | Position | Start |
|---|---|---|
| ELEVATION ONCOLOGY, INC. | Director/Board Member | 2024-01-17 |
Former positions of Darcy Mootz
| Companies | Position | End |
|---|---|---|
| ORIC PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Alpha-9 Oncology, Inc.
 Alpha-9 Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada. | Director/Board Member | - |
| ACHAOGEN | Corporate Officer/Principal | - |
Training of Darcy Mootz
| Harvard University | Doctorate Degree |
| Duke University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| ELEVATION ONCOLOGY, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Alpha-9 Oncology, Inc.
Alpha-9 Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada. | Commercial Services |
- Stock Market
- Insiders
- Darcy Mootz
